UA116452C2 - Режим дозування седативного засобу - Google Patents

Режим дозування седативного засобу

Info

Publication number
UA116452C2
UA116452C2 UAA201502945A UAA201502945A UA116452C2 UA 116452 C2 UA116452 C2 UA 116452C2 UA A201502945 A UAA201502945 A UA A201502945A UA A201502945 A UAA201502945 A UA A201502945A UA 116452 C2 UA116452 C2 UA 116452C2
Authority
UA
Ukraine
Prior art keywords
hypnotic
administering
sedative agent
methyl
general anesthesia
Prior art date
Application number
UAA201502945A
Other languages
English (en)
Inventor
Макі Кондо
Тосіхіко Кономі
Сігехіто Сато
Мацуюкі Доі
Original Assignee
ПАЙОН ЮКей ЛІМІТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПАЙОН ЮКей ЛІМІТЕД filed Critical ПАЙОН ЮКей ЛІМІТЕД
Publication of UA116452C2 publication Critical patent/UA116452C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується седативного способу, що передбачає внутрішньовенне введення седативного засобу, який містить метил-3-[(4S)-8-бром-1-метил-6-(2-піридиніл)-4Н-імідазо[1,2-а][1,4]бензодіазепін-4-іл]пропаноат або його сіль, пацієнту за допомогою режиму дозування, що включає двостадійний спосіб введення.
UAA201502945A 2012-08-31 2013-08-30 Режим дозування седативного засобу UA116452C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012192081 2012-08-31
PCT/JP2013/073414 WO2014034890A1 (ja) 2012-08-31 2013-08-30 催眠鎮静剤の投与方式

Publications (1)

Publication Number Publication Date
UA116452C2 true UA116452C2 (uk) 2018-03-26

Family

ID=50183693

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201502945A UA116452C2 (uk) 2012-08-31 2013-08-30 Режим дозування седативного засобу

Country Status (34)

Country Link
US (2) US20150224114A1 (uk)
EP (1) EP2891494B1 (uk)
JP (1) JP6199869B2 (uk)
KR (1) KR102228598B1 (uk)
CN (1) CN104768557A (uk)
AP (1) AP2015008287A0 (uk)
AU (1) AU2013309860B2 (uk)
BR (1) BR112015004477A8 (uk)
CA (1) CA2883667A1 (uk)
CL (1) CL2015000494A1 (uk)
DK (1) DK2891494T3 (uk)
EA (1) EA027370B1 (uk)
ES (1) ES2959499T3 (uk)
FI (1) FI2891494T3 (uk)
GE (1) GEP201706755B (uk)
HK (1) HK1210588A1 (uk)
HR (1) HRP20231302T1 (uk)
HU (1) HUE063967T2 (uk)
IL (1) IL237373B (uk)
LT (1) LT2891494T (uk)
MA (1) MA37954A1 (uk)
MX (1) MX2015002467A (uk)
MY (1) MY171592A (uk)
NZ (1) NZ705177A (uk)
PE (1) PE20151374A1 (uk)
PH (1) PH12015500381A1 (uk)
PL (1) PL2891494T3 (uk)
PT (1) PT2891494T (uk)
SG (1) SG11201501358SA (uk)
SI (1) SI2891494T1 (uk)
TN (1) TN2015000067A1 (uk)
UA (1) UA116452C2 (uk)
WO (1) WO2014034890A1 (uk)
ZA (1) ZA201501207B (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150081370A (ko) 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106804107B (zh) * 2014-07-23 2019-03-12 江苏恩华络康药物研发有限公司 新的苯并二氮杂*类衍生物及其用途
CN106632342B (zh) * 2015-08-07 2019-01-25 成都倍特药业有限公司 苯并二氮杂*衍生物的2-萘磺酸盐及晶型和它们的制备方法
CN107266452A (zh) * 2016-04-08 2017-10-20 四川科伦药物研究院有限公司 苯并二氮杂*衍生物的盐及其晶体形式、制备方法和用途
CN109641000A (zh) * 2016-04-14 2019-04-16 Paion英国有限公司 经口吸入和经鼻用的苯并二氮杂*类
CN108503644B (zh) * 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
CN108033964B (zh) * 2017-12-28 2021-02-09 杭州奥默医药股份有限公司 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN114588164B (zh) * 2022-04-19 2023-08-11 天津医科大学总医院 瑞马唑仑在预防围术期低体温和寒战中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
KR20150081370A (ko) * 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)

Also Published As

Publication number Publication date
HK1210588A1 (en) 2016-04-29
AU2013309860A1 (en) 2015-03-19
PH12015500381B1 (en) 2015-04-20
BR112015004477A8 (pt) 2019-08-27
CL2015000494A1 (es) 2015-10-02
AP2015008287A0 (en) 2015-02-28
US20220152045A1 (en) 2022-05-19
EP2891494A4 (en) 2016-04-27
JP6199869B2 (ja) 2017-09-20
EP2891494B1 (en) 2023-07-19
TN2015000067A1 (en) 2016-06-29
ES2959499T3 (es) 2024-02-26
PH12015500381A1 (en) 2015-04-20
MY171592A (en) 2019-10-21
EA027370B1 (ru) 2017-07-31
PE20151374A1 (es) 2015-09-25
PT2891494T (pt) 2023-10-25
WO2014034890A1 (ja) 2014-03-06
IL237373B (en) 2020-05-31
MX2015002467A (es) 2015-11-09
FI2891494T3 (fi) 2023-10-16
CN104768557A (zh) 2015-07-08
HRP20231302T1 (hr) 2024-02-02
ZA201501207B (en) 2019-11-27
SG11201501358SA (en) 2015-04-29
CA2883667A1 (en) 2014-03-06
HUE063967T2 (hu) 2024-02-28
PL2891494T3 (pl) 2024-01-03
AU2013309860B2 (en) 2017-12-21
IL237373A0 (en) 2015-04-30
JPWO2014034890A1 (ja) 2016-08-08
DK2891494T3 (da) 2023-10-23
KR20150047573A (ko) 2015-05-04
US20150224114A1 (en) 2015-08-13
GEP201706755B (en) 2017-10-25
EP2891494A1 (en) 2015-07-08
NZ705177A (en) 2018-01-26
BR112015004477A2 (pt) 2017-07-04
SI2891494T1 (sl) 2023-12-29
LT2891494T (lt) 2023-11-10
MA37954A1 (fr) 2018-07-31
KR102228598B1 (ko) 2021-03-15
EA201590467A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
TN2015000067A1 (en) Method for administering hypnotic/sedative agent
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
IN2014MN01755A (uk)
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
NZ713868A (en) Treatment of cancer using coenzyme q10 combination therapies
WO2012023623A3 (ja) ハンター症候群の治療剤
MX2018004328A (es) Composiciones farmaceuticas estabilizantes de camptotecina.
IN2014MN02214A (uk)
MX2022001966A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
MX338746B (es) Vitamina d3 y analogos de la misma para tratar alopecia.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
IN2014DN08598A (uk)
WO2012145575A3 (en) Therapy for leukemia
EP3162804A8 (en) New benzodiazepine derivative and use thereof
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
IN2014DN10134A (uk)
EA032959B1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
UA69624U (uk) Спосіб профілактики загострення хронічного бронхіту у хворих зі сполученим перебігом з пептичною виразкою дванадцятипалої кишки
UA69222U (uk) Спосіб рефлексотерапії хворих з віддаленими наслідками черепно-мозкової травми
UA77030U (uk) Процес профілактики і лікування реперфузійного синдрому при гострій ішемії кінцівок
UA59989U (uk) Спосіб лікування хворих на стеатоз печінки
UA74769U (uk) Спосіб лікування хворих зі стеатозом печінки, поєднаним з хронічним безкам'яним холециститом